IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer

IFM to launch IFM Quattro, along with new incubator, IFM Discovery, and up to two additional subsidiaries focused on select targets of the innate immune system Financing is led by new investor Omega Funds, with participation from existing investors Atla... Biopharmaceuticals, Venture Capital, Personnel IFM Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news